Clinical trials: Large-cell Lymphoma
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134017
- Testing
- Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Follicular Lymphoma, Marginal Zone Lymphoma
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00644189
- Testing
- Clofarabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00274924
- Testing
- filgrastim, rituximab, carboplatin
- Where
- 104 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with…
- Trial name
- NCT01855750
- Testing
- Ibrutinib, Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Argentina and 25 more
- Volunteers
- 838 people
- Sponsor
- Janssen Research & Development, LLC
Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma
Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
This phase I trial studies the side effects and the best dose of crizotinib when given together with combination chemotherapy in treating younger patients with solid tumors or anaplastic large cell lymphoma that has returned or…
- Conditions
- Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
- Trial name
- NCT01606878
- Testing
- Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride
- Where
- 23 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Children's Oncology Group
Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy
The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.
- Trial name
- NCT01510184
- Testing
- Zevalin, Y-90-Zevalin, Rituximab
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 79 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Chronic Myeloproliferative Disorders, Leukemia
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00691015
- Testing
- rituximab, busulfan, carmustine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01273766
- Testing
- deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT00131937
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human…
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03220022
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 19 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Diffuse Large B-Cell
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on…
- Trial name
- NCT02226965
- Testing
- PNT2258
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Non-Hodgkin's Lymphoma
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Objectives The primary objective of this study is to: determine the complete and partial response rates and the toxicity profile of bortezomib (VELCADE, formerly PS-341) when administered in combination with DICE chemotherapy…
- Trial name
- NCT00504751
- Testing
- bortezomib, dexamethasone, ifosfamide, mesna, cisplatin, etoposide, rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Graft Versus Host Disease, Leukemia
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant or peripheral stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00611351
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
NHL, Non Hodgkin Lymphoma
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or…
- Conditions
- NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT04555811
- Testing
- FT596, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large…
- Trial name
- NCT02139592
- Testing
- Brentuximab vedotin (recombinant)
- Where
- Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma.
- Conditions
- Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03113500
- Testing
- Brentuximab Vedotin, Cyclophosphamide, Doxorubicin
- Where
- 5 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- City of Hope Medical Center